NasdaqCM:HJLI

Stock Analysis Report

Hancock Jaffe Laboratories

Executive Summary

Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Risks

  • Hancock Jaffe Laboratories has significant price volatility in the past 3 months.
  • Hancock Jaffe Laboratories is covered by less than 3 analysts.

Share Price & News

How has Hancock Jaffe Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.0%

NasdaqCM:HJLI

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-57.2%

NasdaqCM:HJLI

8.7%

US Medical Equipment

1.7%

US Market

HJLI underperformed the Medical Equipment industry which returned 8.7% over the past year.

HJLI underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

HJLIIndustryMarket
7 Day-2.0%-1.2%1.2%
30 Day-3.9%1.4%4.9%
90 Day-9.9%4.8%3.7%
1 Year-57.2%-57.2%9.6%8.7%3.9%1.7%
3 Yearn/a70.8%65.5%47.2%37.7%
5 Yearn/a130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Hancock Jaffe Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hancock Jaffe Laboratories undervalued based on future cash flows and its price relative to the stock market?

3.7x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Hancock Jaffe Laboratories to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Hancock Jaffe Laboratories to establish if it is available at substantial discount.


Price Based on Earnings

Hancock Jaffe Laboratories is loss making, we can't compare its value to the US Medical Equipment industry average.

Hancock Jaffe Laboratories is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Hancock Jaffe Laboratories, we can't assess if its growth is good value.


Price Based on Value of Assets

Hancock Jaffe Laboratories is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Hancock Jaffe Laboratories expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

-9.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Hancock Jaffe Laboratories's revenue is expected to grow significantly at over 20% yearly.

Hancock Jaffe Laboratories is not considered high growth as it is expected to be loss making for the next 1-3 years.

Hancock Jaffe Laboratories's revenue growth is expected to exceed the United States of America market average.

Unable to compare Hancock Jaffe Laboratories's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Hancock Jaffe Laboratories's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Hancock Jaffe Laboratories will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Hancock Jaffe Laboratories performed over the past 5 years?

-38.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Hancock Jaffe Laboratories does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Hancock Jaffe Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Hancock Jaffe Laboratories's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Hancock Jaffe Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Hancock Jaffe Laboratories has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Hancock Jaffe Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Hancock Jaffe Laboratories's financial position?


Financial Position Analysis

Hancock Jaffe Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Hancock Jaffe Laboratories's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Hancock Jaffe Laboratories's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Hancock Jaffe Laboratories's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 4.1702629987907E+16x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Hancock Jaffe Laboratories has less than a year of cash runway based on current free cash flow.

Hancock Jaffe Laboratories has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.8% each year.


Next Steps

Dividend

What is Hancock Jaffe Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Hancock Jaffe Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Hancock Jaffe Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Hancock Jaffe Laboratories has not reported any payouts.

Unable to verify if Hancock Jaffe Laboratories's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Hancock Jaffe Laboratories has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Hancock Jaffe Laboratories's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Robert Berman (56yo)

1.4yrs

Tenure

US$906,369

Compensation

Mr. Robert A. Berman serves as Chief Executive Officer and Director of Hancock Jaffe Laboratories, Inc. since April 2018. He served as the Chief Executive Officer and President of ITUS Corporation (formerl ...


CEO Compensation Analysis

Robert's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Robert to compare compensation growth.


Management Age and Tenure

1.4yrs

Average Tenure

64yo

Average Age

The average tenure for the Hancock Jaffe Laboratories management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.9yrs

Average Tenure

56yo

Average Age

The average tenure for the Hancock Jaffe Laboratories board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$25,00017 Apr 19
Robert Berman
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares18,382
Max PriceUS$1.36

Ownership Breakdown


Management Team

  • Bob Rankin (66yo)

    CFO, Secretary & Treasurer

    • Tenure: 1.2yrs
    • Compensation: US$403.45k
  • Robert Berman (56yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$906.37k
  • Warren Hancock

    Co-founder

    • Tenure: 32.7yrs
  • Ben Broennimann (62yo)

    Chief Medical Officer of Outside of United States

    • Tenure: 1.4yrs
    • Compensation: US$240.00k
  • Marc Glickman (70yo)

    Senior VP & Chief Medical Officer

    • Tenure: 3.3yrs
    • Compensation: US$362.64k

Board Members

  • Robert Berman (56yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$906.37k
  • Afksendyios Kalangos

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Francis Duhay (58yo)

    Independent Director

    • Tenure: 0.9yrs
    • Compensation: US$91.09k
  • Steve Elias

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Antonios Gasparis

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Wade Dimitri

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Sanjay Shrivastava (51yo)

    Independent Director

    • Tenure: 0.9yrs
    • Compensation: US$91.09k

Company Information

Hancock Jaffe Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hancock Jaffe Laboratories, Inc.
  • Ticker: HJLI
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$17.205m
  • Shares outstanding: 17.92m
  • Website: https://www.hancockjaffe.com

Number of Employees


Location

  • Hancock Jaffe Laboratories, Inc.
  • 70 Doppler
  • Irvine
  • California
  • 92618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HJLINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2018
5HJBST (Boerse-Stuttgart)YesCommon StockDEEURMay 2018

Biography

Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 01:25
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.